Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of SHR-2017 in Postmenopausal Women
NCT05930704Phase 1Unknown
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jul 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoporosis comparing SHR-2017 Injection with Placebo (2 arms). Primary endpoint: Number of participants with adverse events. Status: unknown.
02
Drugs
SHR-2017
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT05930704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05930704.